| Literature DB >> 31507558 |
Iman Dandachi1, Amer Chaddad1, Jason Hanna1, Jessika Matta1, Ziad Daoud1,2.
Abstract
In the last decade, extended-spectrum cephalosporin and carbapenem resistant Gram-negative bacilli (GNB) have been extensively reported in the literature as being disseminated in humans but also in animals and the environment. These resistant organisms often cause treatment challenges due to their wide spectrum of antibiotic resistance. With the emergence of colistin resistance in animals and its subsequent detection in humans, the situation has worsened. Several studies reported the transmission of resistant organisms from animals to humans. Studies from the middle east highlight the spread of resistant organisms in hospitals and to a lesser extent in livestock and the environment. In view of the recent socio-economical conflicts that these countries are facing in addition to the constant population mobilization; we attempt in this review to highlight the gaps of the prevalence of resistance, antibiotic consumption reports, infection control measures and other risk factors contributing in particular to the spread of resistance in these countries. In hospitals, carbapenemases producers appear to be dominant. In contrast, extended spectrum beta lactamases (ESBL) and colistin resistance are becoming a serious problem in animals. This is mainly due to the continuous use of colistin in veterinary medicine even though it is now abandoned in the human sphere. In the environment, despite the small number of reports, ESBL and carbapenemases producers were both detected. This highlights the importance of the latter as a bridge between humans and animals in the transmission chain. In this review, we note that in the majority of the Middle Eastern area, little is known about the level of antibiotic consumption especially in the community and animal farms. Furthermore, some countries are currently facing issues with immigrants, poverty and poor living conditions which has been imposed by the civil war crisis. This all greatly facilitates the dissemination of resistance in all environments. In the one health concept, this work re-emphasizes the need to have global intervention measures to avoid dissemination of antibiotic resistance in humans, animals and the environment in Middle Eastern countries.Entities:
Keywords: ESBL; MDROs; carbapenemases; colistin; one health
Year: 2019 PMID: 31507558 PMCID: PMC6716069 DOI: 10.3389/fmicb.2019.01941
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
FIGURE 1Geographical distribution of ESBL in humans, animals, hospital, and community environment in the Middle East.
Sequence and plasmid types associated with ESBL genes in humans, animals, and environment in the Middle East.
| Iran | CTX-M | Humans | |||
| Hospital environment | |||||
| Community environment | |||||
| TEM | Humans | ||||
| Hospital environment | |||||
| Community environment | |||||
| SHV | Humans | ||||
| Animals | |||||
| Hospital environment | |||||
| OXA | Humans | ||||
| Hospital environment | |||||
| GES | Humans | ||||
| VEB | Humans | ||||
| PER | Humans | ||||
| Turkey | CTX-M | Humans/community environment | – | ||
| Animals | A, D, B1, B2 | ||||
| Humans | |||||
| Humans | |||||
| TEM | Humans/animals | ||||
| Humans | |||||
| Humans | |||||
| SHV | Humans | ||||
| Animals | A, D, B1, B2 | ||||
| Community environment | |||||
| OXA | Humans | ||||
| Community environment | |||||
| GES | Humans | ||||
| VEB | Humans | ||||
| PER | Humans | ||||
| Lebanon | CTX-M | Humans | |||
| Animals | ST10, ST617, ST58, ST69, ST1303, ST156, ST5470, ST354, ST155, ST3224 | ||||
| Community environment | ST328, ST405, ST34, ST48, ST131, ST120, ST2067, ST10, ST38, ST410 | IncFII | |||
| ST38, ST1431, ST46 | IncFIA | ||||
| ST212 | IncY | ||||
| ST617, ST4144, ST6470, ST6222, ST90, ST38, ST4608, ST6894, ST127 | |||||
| ST22, ST336, ST15, ST16 | IncFIIk | ||||
| IncY | |||||
| IncY | |||||
| Hospital environment | |||||
| TEM | Humans | ||||
| Animals | |||||
| Hospital environment | |||||
| SHV | Humans | ||||
| Animals | |||||
| Community environment | ST46 | IncFII | |||
| ST617, ST6470, ST90, ST4608, ST6480, ST4144 | |||||
| SHV | Hospital environment | ||||
| VEB | Humans | ||||
| Palestine/Israel | CTX-M | Humans | ST1, ST2, ST39, ST131, ST472, ST473, ST474, ST475, ST476, ST477 | ||
| Animals | |||||
| TEM | Humans | ||||
| SHV | Humans | ||||
| Animals | |||||
| Jordan | CTX-M | Humans | ST131 | ||
| A2, C | |||||
| Iraq | CTX-M | Humans | |||
| TEM | Humans | ||||
| SHV | Humans | ||||
| OXA | Humans | ST244, ST308 | |||
| VEB | Humans | ST235 | |||
| PER | Humans | ||||
| Bahrain | CTX-M | Humans | |||
| TEM | Humans | ||||
| SHV | Humans | ||||
| Qatar | CTX-M | Humans | |||
| TEM | Humans | ||||
| SHV | Humans | ||||
| United Arab Emirates | CTX-M | Humans | ST131 | IncFII-FIA-FIB | |
| ST131 | |||||
| SHV | Humans | ||||
| Oman | CTX-M | Humans | |||
| Yemen | CTX-M | Humans | ST131 | ||
| ST1399, ST340, ST405, ST147, ST29 | |||||
| SHV | Humans | ST1399, ST340, ST405, ST147 | |||
| Kuwait | CTX-M | Humans | ST131, ST405, ST38 | ||
| SHV | Humans | ST131 | |||
| KSA | CTX-M | Humans | ST131, ST493, ST73, ST2346, ST1193, ST92, ST421, ST636, ST410, ST3268, ST120, ST602, | ||
| ST224, ST1196, ST2852, ST58, ST1011, ST6438, | |||||
| ST167, ST8162, ST4981, ST1284, ST648, ST117, ST457, ST394, ST69, ST38, ST10 | |||||
| ST195 | |||||
| Community environment | |||||
| TEM | Humans | ST493, ST73, ST131, ST2346, ST1193, ST92, ST421, ST636, ST410, ST4040, ST46, ST38, ST3268, ST405 | |||
| ST648, ST117, ST394, ST69, ST8162, ST4981, ST1284 | |||||
| ST195 | |||||
| Animals | |||||
| SHV | Humans | ||||
| Animals | |||||
| OXA | Humans | ||||
| GES | Humans | ST1, ST2, ST15, ST17, ST113, ST114, ST115, ST116 | |||
| VEB | Humans | ||||
| Egypt | CTX-M | Humans | ST405, ST68, ST131, ST648; Phylogroup A, B1, B2, D | ||
| Animals | ST131 | IncFII | |||
| D | |||||
| TEM | Humans | ||||
| Animals | B1, C, D | ||||
| SHV | Humans | ST68, Phylogroups A and D | |||
| Animals | D | ||||
| OXA | Animals | C. B2 |
Sequence and plasmid types associated with carbapenemase genes in humans, animals, and environment in the Middle East.
| Iran | Class D oxacillinases | Humans | ST131, ST167, ST1431, ST5005, ST889, ST10, ST3737, ST410, ST5114, ST5164, ST315, | ||
| ST6350, ST648, ST167, ST410, ST431, ST3134 | IncL/M | ||||
| ST178, ST6826 | IncA/C | ||||
| A, B | |||||
| ST2 | |||||
| Hospital environment | |||||
| KPC | Humans | B | |||
| NDM | Humans | C,D, ST167, ST131 | |||
| ST3044, ST167, ST178, ST6826 | IncA/C | ||||
| ST315 | IncL/M | ||||
| C, D | |||||
| ST11, ST893 | IncFII | ||||
| Community environment | |||||
| Hospital environment | |||||
| VIM | Humans | ST13, ST392 | |||
| Community environment | |||||
| IMP | Humans | ||||
| Community environment | |||||
| Hospital environment | |||||
| Turkey | Class D oxacillinases | Humans | |||
| ST11, ST258, ST16 | |||||
| ST2, ST15, ST157, ST10, ST158 | |||||
| NDM | Humans | ||||
| VIM | Humans | ||||
| IMP | Humans | ||||
| Palestine/Israel | Class D oxacillinases | Humans | IncL/M | ||
| KPC | Humans | ST512 | |||
| ST340, ST277, ST376 | |||||
| ST327, ST512, ST258 | pKpQIL | ||||
| Hospital and community environment | Enterobacteriaceae | ||||
| NDM | Humans | ST103, ST2, ST183 | |||
| Hospital and community environment | Enterobacteriaceae | ||||
| VIM | Humans | ST1562, ST1563, ST1564 | |||
| Lebanon | Class D oxacillinases | Humans | ST405 | IncL/M | |
| IncL/M | |||||
| IncL/M | |||||
| IncL/M | |||||
| IncL/M | |||||
| ST2, ST25, ST1, ST570, ST85, ST600 | |||||
| Animals | ST38 | ||||
| ST2, ST491, ST493, ST20, ST492 | |||||
| Community environment | ST38 | IncHI2 | |||
| – | IncL | ||||
| ST16 | IncL | ||||
| NDM | Humans | ST14, ST25 | |||
| Hospital environment | |||||
| VIM | Humans | ST233, ST699, ST654 | |||
| Animals | ST1759, ST1760, ST1761, ST1762 | ||||
| IMP | Humans | ST446, ST654 | |||
| Syria | Class D oxacillinases | Humans | ST38 | ||
| ST101, ST1633 | |||||
| NDM | Humans | ||||
| ST278 | |||||
| ST85 | |||||
| Jordan | Class D oxacillinase | Humans | A1, A3, B | IncL/M | |
| Hospital environment | |||||
| NDM | Humans | ||||
| A2, C | |||||
| IncFIB, IncFII | |||||
| VIM | Humans | ||||
| Iraq | Class D oxacillinases | Humans | ST2, ST136, ST194, ST623, ST792, ST793 | ||
| NDM | Humans | ||||
| IMP | Humans | ||||
| Kuwait | Class D oxacillinases | Humans | ST405, ST38 | ||
| ST677, ST16, ST107, ST485 | |||||
| ST158 | pK50a | ||||
| ST195, ST208, ST229, ST436, ST450, ST452, ST499 | |||||
| NDM | Humans | ST448 | IncX3 | ||
| VIM | Humans | IncA/C | |||
| IncA/C | |||||
| IMP | Humans | ||||
| KSA | Class D oxacillinases | Humans | |||
| ST29, ST709, ST37, ST111, ST974, ST29, ST199, ST48, ST348, ST152, ST340, ST17, ST298, ST16, | |||||
| ST11, ST353 | |||||
| ST2, ST19, ST20, ST25, ST236, ST1096, ST945, ST208, | |||||
| ST450, ST452, ST499, ST195, ST229, ST436, | |||||
| NDM | Humans | ST152, ST348, ST199, ST1045 | |||
| Community environment | |||||
| VIM | Humans | ||||
| ST1, ST2, ST195, ST196, ST487, ST489, ST20 | |||||
| IMP | Humans | ST1, ST2, ST195, ST196, ST487, ST489, ST20 | |||
| Bahrain | Class D oxacillinases | Humans | ST208, ST452 | ||
| VIM | Humans | ||||
| Qatar | Class D oxacillinases | Humans | |||
| ST229 | |||||
| NDM | Humans | ||||
| VIM | Humans | ||||
| United Arab Emirates | Class D oxacillinases | Humans | |||
| ST14, ST15, ST23, ST48 | |||||
| KPC | Humans | ST14 | IncX3 | ||
| NDM | Humans | ||||
| ST14 | HI1b | ||||
| ST147 | IncFII | ||||
| VIM | Humans | ||||
| Oman | Class D oxacillinases | Humans | ST648 | IncL/M | |
| ST138 | |||||
| ST753, ST754 | IncL/M | ||||
| ST195 | |||||
| NDM | Humans | ST2527 | IncF | ||
| ST4107 | IncX3 | ||||
| ST15, ST147 | IncH1B | ||||
| ST372 | IncFII | ||||
| ST11 | IncL/M, IncH1B | ||||
| VIM | Humans | ||||
| Yemen | Class D Oxacillinase | Humans | ST2 | ||
| NDM | Humans | ST1399, ST147, ST29, ST405, ST340 | |||
| Egypt | Class D oxacillinases | Humans | ST101, ST648 | ||
| ST331, ST410, ST208, ST108, ST411, ST409, ST236 | |||||
| Animals | |||||
| KPC | Humans | ||||
| Animals | |||||
| NDM | Humans | ST5018 | Incl1-ly | ||
| ST147, ST11, ST17 | IncR | ||||
| ST103 | |||||
| ST233 | |||||
| Animals | |||||
| VIM | Humans | A, B | |||
| ST233, ST198, ST303, ST629, ST507, ST406, ST274, ST990, ST683, ST884, ST738 |
Mechanisms of colistin resistance described in GNB in the Middle East.
| Iran | Clinical samples | pmrB∗ | |||
| pmrA/B∗ | |||||
| mgrB∗ | |||||
| MexAB-OprM/MexXY-OprM∗∗ | |||||
| Lebanon | Clinical samples | ST268 | mgrB∗ | ||
| ST2296 | mgrB∗, PhoQ∗ | ||||
| ST348 | pmrA/B∗ | ||||
| Poultry | ST515 | ||||
| Swine | |||||
| Palestine | Clinical samples | mgrB∗ | |||
| ST512, ST76 | mgrB∗ | ||||
| Bahrain | Clinical samples | ST648, ST224 | |||
| Qatar | Clinical samples | ST95 | |||
| United Arab Emirates | Clinical samples | ST147 | mgrB∗ | ||
| ST131 | |||||
| Oman | Clinical samples | ST10 | |||
| KSA | Clinical samples | ST974, ST37, ST709, ST348, ST37 | PhoP∗ | ||
| ST14, ST15, ST16, ST22, ST48, ST101, ST152, ST307 | mgrB∗ | ||||
| ST15 | mgrB∗, phoP∗ | ||||
| ST68 | |||||
| Egypt | Clinical samples | pmrCAB∗ | |||
| Animal | ST10 | ||||
FIGURE 2Geographical distribution of carbapenemases in humans, animals, hospital, and community environment in the Middle East.
FIGURE 3Geographical distribution of colistin resistance in humans and animals in the Middle East.